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The aim of this study was to characterize the in vitro and in vivo metabolism of 2‐
aminoindane (2,3‐dihydro‐1H‐inden‐2‐amine, 2‐AI), and N‐methyl‐2‐aminoindane
(N‐methyl‐2,3‐dihydro‐1H‐inden‐2‐amine, NM‐2‐AI) after incubations using pooled
human liver microsomes (pHLMs), pooled human liver S9 fraction (pS9), and rat urine
after oral administration. After analysis using liquid chromatography coupled to high‐
resolution mass spectrometry, pHLM incubations revealed that 2‐AI was left unme-
tabolized, while NM‐2‐AI formed a hydroxylamine and diastereomers of a metabolite
formed after hydroxylation in beta position. Incubations using pS9 led to the forma-
tion of an acetyl conjugation in the case of 2‐AI and merely a hydroxylamine for
NM‐2‐AI. Investigations on rat urine showed that 2‐AI was hydroxylated also forming
diasteromers as described for NM‐2‐AI or acetylated similar to incubations using pS9.
All hydroxylated metabolites of NM‐2‐AI except the hydroxylamine were found in rat
urine as additional sulfates. Assuming similar patterns in humans, urine screening pro-
cedures might be focused on the parent compounds but should also include their
metabolites. An activity screening using human recombinant N‐acetyl transferase
(NAT) isoforms 1 and 2 revealed that 2‐AI was acetylated exclusively by NAT2, which
is polymorphically expressed.
KEYWORDS
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2‐Aminoindane (2,3‐dihydro‐1H‐inden‐2‐amine, 2‐AI), and N‐methyl‐
2‐aminoindane (N‐methyl‐2,3‐dihydro‐1H‐inden‐2‐amine, NM‐2‐AI)
are emerging new psychoactive substances (NPS) that were recently
offered in online shops.1 2‐AI and NM‐2‐AI are indirectly sympathomi-
metic acting drugs causing a transporter mediated increased release of
monoamines in the synaptic cleft.2,3 Unlike substituted aminoindanes,- - - - - - - - - - - - - - - - - - - - - - - - - -
the Creative Commons Attributio
d, the use is non‐commercial and
blished by John Wiley & Sons Ltthe selective inhibition of 2‐AI is merely limited to the norephedrine
reuptake transporter (NET); it also releases norephedrine (NE) and
dopamine (DA).4 NM‐2‐AI has more stimulant properties but a lower
potency than 2‐AI. It inhibits the NET and the DA transporter (DAT)
selectively and causes an efflux of NE and DA leading to their accumu-
lation in the synaptic cleft. Both aminoindanes influence the seroto-
nergic neurotransmission system.4 Typical symptoms after
overdosing are tachycardia, hyperpnoea, increased transpiration, and- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
n‐NonCommercial‐NoDerivs License, which permits use and distribution in any
no modifications or adaptations are made.
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MANIER ET AL.146dehydration as well as anxiety, depression, and paranoia.5 Consump-
tion of 5‐Methoxy‐2‐aminoindane (MEAI) resulted in a mild euphoric,
alcohol‐like tipsy experience and a reduced desire to consume alco-
holic beverages. Cytotoxic effects were also demonstrated in concen-
trations of 500 and 1000 mg/L with calculated IC50 value of
approximately 400 mg/L for rat brain striatum primary neurons and
human primary healthy hepatocytes.6
Before analyzing urine samples for the presence of NPS such as 2‐
AI and NM‐2‐AI, suitable analytical targets need to be defined. As
these targets are often unknown, metabolism studies are necessary7
Different in vitro and in vivo models are available for this purpose.8
However, it is well known that (human) in vitro models are only
partially able to simulate metabolic processes that may occur in a living
system. Identification of metabolites in vivo that have not been
detected in vitro is therefore not uncommon.8 Thus, the complemen-
tary use of in vitro and in vivo methods to predict human metabolism
should be preferred. The aim of this study was therefore to character-
ize the metabolism of 2‐AI and NM‐2‐AI using pooled human liver
microsomes (pHLMs), pooled human liver S9 fraction (pS9), and rat
urine after oral administration.2 | EXPERIMENTAL
2.1 | Chemicals and reagents
2‐AI was purchased at Sigma‐Aldrich (Taufkirchen, Germany) and NM‐
2‐AI was ordered from GR8 Research Chemicals‐EU (https://www.
gr8researchchemicals‐eu.com). Acetyl coenzyme A (AcCoA),
acetylcarnitine, acetylcarnitine transferase (AcT), dithiotreitole (DTT),
reduced glutathione (GSH), 3′‐phosphoadenosine‐5′‐phosphosulfate
(PAPS), S‐(5′‐adenosyl)‐L‐methionine (SAM), MgCl2, K2HPO4,
KH2PO4, superoxide dismutase (SOD), isocitratedehydrogenase
(IDH), isocitrate, tris (hydroxymethyl)‐aminomethane (TRIS),
ammoniumformate, and formic acid were received from Sigma‐Aldrich
(Taufkirchen, Germany). NADP‐Na2, acetonitrile [liquid
chromatography–mass spectrometry (LC–MS) grade], ammonium for-
mate (analytical grade), formic acid (LC–MS grade), methanol (LC–MS
grade), ethylenediaminetetraacetic acid (EDTA), triethanolamine
(TEA), and all other chemicals and reagents (analytical grade) were
obtained from VWR (Darmstadt, Germany). Water was purified using
a Millipore filtration unit (18.2 Ω × cm water resistance). pHLM
(20 mg microsomal protein/mL, 330 pmol total CYP/mg protein, from
34 individual donors), pS9 (20 mg protein/mL, from 30 individual
donors), UGT reaction mix solution A (25mM UDP‐glucuronic acid),
and UGT reaction mix solution B (250mM Tris–HCl, 40mM MgCl2,
and 0.125 mg/mL alamethicin) were obtained from Corning (Amster-
dam, Netherlands). Baculovirus infected insect cell‐expressed human
arylamine N‐acetyltransferase 1 (NAT1, 1*4, wild type allele) and
NAT2 (2*4, wild type allele) were from BD Biosciences (Heidelberg,
Germany). After delivery, the enzymes and liver preparations were
thawed at 37°C, aliquoted, snap‐frozen in liquid nitrogen, and stored
at −80°C until use.2.2 | Liquid chromatography–high resolution tandem
mass spectrometry apparatus for identification of
metabolites
Analysis was performed according to a previously published study.9
Details can be found in the Supporting Information.2.3 | Incubations using pHLM, pS9, and recombinant
NAT isoenzymes and collection of rat urine samples
Conditions were similar to previous studies and further details can be
found in the Supporting Information.10-122.4 | Sample preparation for identification of phase I
and II metabolites in rat urine by liquid
chromatography–high resolution tandem mass
spectrometry
As described elsewhere,13 a 100‐μL aliquot of rat urine was vortexed
for 2 minutes after addition of 500 μL acetonitrile. The mixture was
centrifuged for 2 minutes at 10,000 rpm. The supernatant was trans-
ferred into a glass vial and evaporated to dryness at 70°C under a
stream of nitrogen. The residue was dissolved in 50 μL of a mixture
of eluent A and B (1:1; v/v) and a 1‐μL aliquot was injected onto the
Orbitrap‐based liquid chromatography−high resolution tandem mass
spectrometry (LC−HRMS/MS) system. The second urine sample prep-
aration was performed as described in previously published litera-
ture.14 Five‐hundred μL urine was mixed with 2 mL deionized water.
The sample was loaded on a HCX solid phase extraction (SPE) car-
tridge, which had previously been conditioned with 1 mL methanol
and 1 mL aqua destillata. Washing steps were performed with 1 mL
aqua destillata, 1 mL 0.01 M hydrochloric acid and methanol after
the sample passed through the cartridge. Remaining basic compounds
were eluted by using 1 mL of a freshly prepared mixture of methanol
and 32% aqueous ammonia (98:2, v/v). The eluates were evaporated
to dryness under a gentle stream of nitrogen at 70°C. After reconsti-
tution of residues with 50 μL methanol, 1 μL of the sample was
injected onto the LC−HRMS/MS system for analysis.3 | RESULTS AND DISCUSSION
3.1 | Proposed fragmentation patterns after
LC−HRMS/MS and tentative identification of
metabolites
Positive electrospray ionization (ESI+) spectra of the metabolites are
given in Figures 1 and 2, ordered by m/z and retention time. Metabo-
lites were identified by comparing the MS2 spectra of the metabolite
with those of the parent compounds. In case of 2‐AI (Figure 1A),
cleavage of the amino group lead to the indan fragment ion with
m/z 117.0698 (C9H9) and the indan fragment ion with m/z
115.0542 (C9H7). Further fragmentation of the ring system led to
FIGURE 1 ESI+ spectra of 2‐AI and its phase I and II metabolites sorted by mass of protonated molecule. Fragments with accurate mass,
calculated elemental formula, and mass error value in parts per million (ppm)
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FIGURE 2 ESI+ spectra of NM‐2‐AI and its
phase I and II metabolites sorted by mass of
protonated molecule. Fragments with
accurate mass, calculated elemental formula,
and mass error value in parts per million (ppm)
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FIGURE 3 Metabolic pathways of 2‐AI. RU = rat urine, pS9 = pooled
human liver S9 fraction. Acetylation is indicated by a suffixed ac
MANIER ET AL. 149the formation of a tropylium ion with m/z 91.0542 (C7H7). 2‐AI
formed diastereomers after hydroxylation in beta position of the
amino group (2 and 3 in Figure 2) with m/z 150.0913 (C9H12ON).
The applied method could not determine the exact configuration of
each metabolite and only diasteromers could be distinguished. Thus,
they are discussed in the following. It seemed that for (1S,2S)‐ and
(1R,2R)‐isomers the elimination of the amino group was preferred,
forming the corresponding fragment ion with m/z 133.0647
(C9H9O). This elimination showed a characteristic shift of the parent
ion by −17.0266 u (NH3). Ring opening resulted in the fragment ion
with m/z 105.0698 (C8H9). Further fragmentation led to the fragment
ion with m/z 86.0600 (C4H8ON) and the fragment ion with m/z
79.0542 (C6H7). For the (1S,2R)‐ and (1R,2S)‐isomers, the elimination
of the hydroxy group was preferred, forming the corresponding frag-
ment ion with m/z 132.0807 (C9H10N). Further fragmentation was
similar to the aforementioned (1S,2S)‐ and (1R,2R)‐isomers. One pos-
sible explanation for this observation might be that the protonated
hydroxy group is a better leaving group than the protonated amine.
Since the elimination of the hydroxy group is only preferred in
(1S,2R)‐ and (1R,2S)‐isomers, it is likely that the hydroxy group forms
a hydrogen bond with the protonated amine enabling the molecule
to eliminate water. In (1S,2S)‐ and (1R,2R)‐isomers the formation of
such a leaving group by hydrogen bonds is not possible leaving the
protonated amine ion as the prioritized leaving group for elimination
reactions. For N‐acetyl‐2‐AI (Figure 2D), which was detected with
m/z 176.1069 (C11H14ON), the fragmentation was almost similar to
the parent compound after cleavage of the acetyl group indicated by
a shift of −42.0104 u (C2H2O). Additionally, an acetamide ion with
m/z 60.0443 (C2H6ON) was detected that was not present in any
other spectra.
NM‐2‐AI (Figure 2A) showed a similar fragmentation compared to
2‐AI. After elimination of the amino group, the indan fragment ion
with m/z 117.0698 (C9H9) was formed. Ring opening resulted in the
formation of a tropylium ion with m/z 91.0542 (C7H7). NM‐2‐AI also
formed diasteromers after hydroxylation (Figure 2B and 2C) with
m/z 164.1069 (C10H14ON). For the (1S,2S)‐ and (1R,2R)‐isomers, the
more dominant fragmentation step was again the loss of the amino
group instead of water, forming the corresponding fragment ion with
m/z 133.0647 (C9H90). The fragment ion with m/z 146.0964 that
resulted after elimination of the hydroxy group was also formed but
with a much lower extent. Further fragmentation steps were similar
to the corresponding diastereomer of 2‐AI. For the (1S,2R)‐ and
(1R,2S)‐isomers, the elimination of the hydroxy group was preferred,
forming the fragment ion with m/z 146.0964 (C10H12N). Further frag-
mentation led to the fragment ion with m/z 131.0729 (C9H9N) and
the fragment ion with m/z 117.0698 (C9H9). Ring opening resulted
in the fragment ion with m/z 105.0698 (C8H9). For the respective
O‐sulfated metabolites (Figure 2E and 2F) with m/z 244.0637
(C10H14O4NS), the elimination of the sulfate group was preferred
instead of the loss of the substituted amino group, forming the corre-
sponding aglycon with m/z 164.1069 (C10H14ON). The fragment ion
with m/z 213.0215 (C9H9O4S) that resulted after cleavage of the
methylated amino group was also formed, but with a much lowerextent. Further fragmentation steps were similar that occurred for
the corresponding phase I metabolite.3.2 | Metabolites found in incubations using pHLM
As no metabolites of 2‐AI were found, it can be assumed that it is only
sparsely metabolized also in vivo. N‐Hydroxylation (4 in Figure 4) and
aliphatic hydroxylation (2 and 3 in Figure 4) were found for NM‐2‐AI.3.3 | Metabolites found in incubations using pS9
2‐AI was metabolized by N‐acetylation (1Ac in Figure 3), a metabolic
step that was not able to be catalyzed by pHLM since NAT is located
in the cytosol of liver cells. NM‐2‐AI was N‐hydroxylated forming a
hydroxylamine (4 in Figure 4). Although identified after incubation
with pHLM, the hydroxy metabolite formed after hydroxylation of
the aliphatic ring system was not detected. This might be explained
by the lower CYP activity of the pS9 fraction compared to pHLM.3.4 | Activity studies using recombinant NAT
isoenzymes
As the NAT2 is polymorphically expressed leading to different possible
rates of acetylation in different individuals, activity studies are impor-
tant.12 NM‐2‐AI was not N‐acetylated, most probably due to the steric
restriction caused by the methyl substituent. N‐Acetyl‐2‐AI was
detected in incubations using pS9 and in incubations using the NAT2
isoenzyme. This is in accordance with the results of other studies that
found a higher affinity of NAT2 toward alkylamines, such as the
reversible dopamine‐β‐hydroxylase inhibitor etamicastat.15 Since 2‐
AI is only metabolized by a few metabolic steps, the occurrence of
polymorphically expressed enzymes being involved in its metabolism
may lead to individually varying plasma concentrations and elimination
half‐lives.3.5 | Identification of phase I and phase II
metabolites in rat urine
2‐AI was hydroxylated in beta position of the amine moiety leading to
diasteromers (2 and 3 in Figure 3). In addition, the N‐acetylated
metabolite was detected (1Ac in Figure 3). NM‐2‐AI was also
FIGURE 4 Metabolic pathways of NM‐2‐AI.
RU = rat urine, pS9 = pooled human liver S9
fraction. Sulfates are indicated by a suffixed S
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sponding (E)/(Z)‐isomers (2 and 3 in Figure 4). In addition to in vitro
incubations hydroxy NM‐2‐AI underwent sulfation leading to the cor-
responding sulfates of the diasteromers (2S and 3S in Figure 4).3.6 | Proposed metabolic pathways
2‐AI was sparsely metabolized. Hydroxylation (1 in Figure 3) in beta
position of the amine moiety led to corresponding diasteromers (2
and 3 in Figure 3). N‐acetylation was observed and led to metabolite
1Ac in Figure 3. Similar to 2‐AI, the hydroxylation of NM‐2‐AI in beta
position of the amine moiety led to the formation of corresponding
diasteromers (2 and 3 Figure 4). Subsequent sulfation was also
observed and led to the sulfated diasteromers (2S and 3S in Figure 4
). Hydroxylation on the amino group led to the formation of a hydrox-
ylamine metabolite (4 in Figure 4 ).
These findings are in line with previous studies. The metabolism of
the related compound 5,6‐methylenedioxy‐2‐aminoindane (MDAI) in
rats was investigated by Zidkova et al by analyzing urine samples using
HRMS amongst others.16 The main metabolic pathways were found to
be oxidative demethylenation followed by O‐methylation and N‐
acetylation as well as formation of glucuronides and sulfates. How-
ever, the main portion of administered MDAI was excreted
unchanged.4 | CONCLUSIONS
The investigated aminoindanes were metabolized to a considerably
low extend. 2‐AI was merely hydroxylated and thereby formed
diasteromers which were clearly distinguishable by their fragmenta-
tion. Acetylation of the amine moiety was the only metabolic reaction
that was detectable in vitro while also occurring in vivo. Incubations
using isolated isoforms of N‐acetyl transferases revealed that this
reaction was catalyzed by NAT2, a polymorphically expressed enzyme
that might influence the hepatic elimination of 2‐AI. The metabolism
of NM‐2‐AI was quite similar to that of 2‐AI. It also formed
diasteromers after hydroxylation which additionally underwent
sulfation. N‐Acetylation was not detected for NM‐2‐AI but hydroxyl-
ation at the amine moiety led to the formation of a hydroxylamine.ACKNOWLEDGEMENTS
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